Testing TH-302, in Combination With Preoperative Chemoradiotherapy, in Esophageal Cancer.
Status:
Withdrawn
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Open-label, single-center phase 1 study of an investigational agent TH-302 and standard
chemoradiotherapy with a 3+3 dose escalation design through 3 dose levels.
Phase:
Phase 1
Details
Lead Sponsor:
Maastricht Radiation Oncology
Collaborators:
Threshold Pharmaceuticals Zuyderland Medical Centre